Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Last trade$319.91
Day change-$0.71 (-0.22%)
Day range$319.20 – $321.40
Volume170,433
Market cap$12.64B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$12.64B
Price / earnings
80.48×
Price / book
7.98×
Price / sales
8.1×
EV / sales
7.95×
EV / EBITDA
59.25×
Profitability
Earnings per share
$3.98
Return on assets
7.75%
Return on equity
9.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
5.89×
Quick ratio
3.92×
Cash ratio
1.09×
Cash flow
Price / cash flow
48.41×
Price / free cash flow
63.09×
Free cash flow
$200.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PEN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$410.15M
$390.05M
$374.76M
$385.39M
$354.69M
$339.46M
$324.14M
$315.52M
Cost of revenue
$129.84M
$125.1M
$121.35M
$123.26M
$114.27M
$115.45M
$108.26M
$104.8M
Gross profit
$280.3M
$264.94M
$253.41M
$262.13M
$240.42M
$224.01M
$215.88M
$210.72M
Selling, general and administrative
$204.2M
$198.51M
$192.8M
$181.1M
$168.9M
$159.96M
$153.46M
$147.94M
Research and development
$25.36M
$25.4M
$22.38M
$21.79M
$22.68M
$23.22M
$22.08M
$20.01M
Total operating expenses
$229.56M
$223.91M
$215.18M
$202.9M
$191.58M
$183.18M
$175.53M
$167.95M
Operating income
$50.74M
$41.04M
$38.23M
$59.23M
$48.84M
$40.83M
$40.35M
$42.78M
Interest expense
$0
-$311K
$0
$0
$0
-$319K
$0
$0
Income before taxes
$56.32M
$46.19M
$41.69M
$63.63M
$52.33M
$45.31M
$43.86M
$44.34M
Income taxes
$14.04M
$11.38M
$9.1M
$16.29M
$6.47M
$40K
$4.64M
$10.66M
Net income
$42.28M
$34.81M
$32.58M
$47.34M
$45.85M
$45.27M
$39.22M
$33.68M
Net income attributable to common shareholders
$42.28M
$34.81M
$32.58M
$47.34M
$45.85M
$45.27M
$39.22M
$33.68M
EBITDA
$56.21M
$46.65M
$42.81M
$63.69M
$51.33M
$46.34M
$45.37M
$47.16M
Basic earnings per share
$1.07
$0.88
$0.83
$1.21
$1.17
$1.17
$1.02
$0.88
Diluted earnings per share
$1.07
$0.88
$0.82
$1.20
$1.17
$1.15
$1.00
$0.85
Recent news
Company coverage with links to the original publishers.
In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.
A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.
Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.
Incuvate has filed a patent-infringement lawsuit against Penumbra in U.S. District Court for the Northern District of California, alleging that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System and related components infringe five Incuvate patents covering real-time aspiration monitoring technology. Incuvate is seeking damages, injunctive relief, and other remedies.
GuideAI Health Corp. announced the appointment of renowned interventional radiologist Dr. James Benenati, Chief Medical Officer of Penumbra Inc., to its Advisory Board following FDA 510(k) clearance of its VAOT software. VAOT is an AI-based triage tool designed to assist radiologists in identifying peripheral arterial disease and vascular occlusion in the lower extremities to enable earlier diagnosis and intervention.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.